Correction

Our article *Nanomedicines – what are they?* (*DTB* 2011; 49: 58-60) reported that medicines containing nanoparticles available in the EU include oral suspensions of aprepitant (Emend) and sirolimus (Rapamune). The source of this information was a European Medicines Agency document, stating that medicinal products containing nanoparticles in the form of "suspensions (i.e. Rapamune, Emend) have already been granted Marketing Authorisations within the Community under the existing regulatory framework".[1] We have since learned that there are no oral suspension formulations of these drugs marketed in the EU.

1. Committee for Medicinal Products for Human Use, 2006. *Reflection paper on nanotechnology-based medicinal products for human use* [online]. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/01/WC500069728.pdf [Accessed 26 August 2011].

DOI: 10.1136/dtb.2011.02.0057

DTB: first published as 10.1136/dtb.2011.02.0057 on 15 September 2011. Downloaded from http://dtb.bmj.com/ on April 26, 2024 by guest. Protected by copyright.